JPMorgan lowered the firm’s price target on Edgewise Therapeutics (EWTX) to $30 from $40 and keeps an Overweight rating on the shares. JPMorgan also removed the stock from its Analyst Focus List. The firm is took a more conservative approach to sevasemten in its lead neuromuscular indications post the Q2 report. However, JPMorgan’s our positive fundamental view of Edgewise remains, as it sees the company’s cardiovascular assets driving most value for the stock in the mid- to longer-term.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- Edgewise Therapeutics Advances in Muscular Dystrophy Trials
- Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 7/30/2025, According to Top Analysts